Polyherbal dietary supplementation for prediabetic adults: Study protocol for a randomized controlled trial
PublisherBioMed Central Ltd.
MetadataShow full item record
AbstractBackground: Prediabetes describes a state of hyperglycemia outside of normal limits that does not meet the criteria for diabetes diagnosis, is generally symptomless, and affects an estimated 38% of adults in the United States. Prediabetes typically precedes the diagnosis of type 2 diabetes, which accounts for increased morbidity and mortality. Although the use of dietary and herbal supplements is popular worldwide, and a variety of single herbal medicines have been examined for glycemic management, the potential of increasingly common polyherbal formulations to return glycemic parameters to normal ranges among adults with prediabetes remains largely unexplored. The purpose of this study is to evaluate the efficacy of a commercially available, polyherbal dietary supplement on glycemic and lipid parameters in prediabetic individuals. Methods: In this multi-site, double-blinded, randomized controlled clinical trial, 40 participants with prediabetes will be randomized to either a daily oral polyherbal dietary supplement (GlucoSupreme™ Herbal; Designs for Health®, Suffield, CT, USA; containing cinnamon bark (Cinnamomum cassia), banaba leaf (Lagerstroemia speciosa standardized to 1% corosolic acid), kudzu root (Pueraria lobata standardized to 40% isoflavones), fenugreek seed (Trigonella foenum-graceum standardized to 60% saponins), gymnema leaf (Gymnema sylvestre standardized to 25% gymnemic acid), American ginseng root (Panax quinquefolius standardized to 5% ginsenosides), and berberine HCl derived from bark (Berberis aristata)) or placebo for 12 weeks. Short-, medium-, and comparatively long-term markers of glycemic control (blood glucose and fasting insulin, fructosamine, and glycated hemoglobin/A1c, respectively), and other glycemic parameters (GlycoMark, ?-cell function, and insulin sensitivity/resistance) will be obtained. Lipid profile (total cholesterol, LDL, HDL, and triglycerides), inflammation (hs-CRP), progression to type 2 diabetes mellitus, as well as safety indices (ALT, AST) will be obtained. An intention-to-treat analysis will be used to assess changes in study outcomes. Discussion: Treatment options for adults with prediabetes are currently limited. This study aims to evaluate the safety and efficacy of a commercially available dietary supplement in the popular, but as yet insufficiently studied, category of polyherbal formulas for the management of glycemic parameters and other biomarkers associated with prediabetes. Trial registration: ClinicalTrials.gov, ID: NCT03388762. Retrospectively registered on 4 January 2018. © 2019 The Author(s).
Glucose Metabolism Disorders
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85059676154&doi=10.1186%2fs13063-018-3032-6&partnerID=40&md5=2fc73e9fcff814c5f12767dbe73fb98b; http://hdl.handle.net/10713/8657
- Acupuncture paired with herbal medicine for prediabetes: study protocol for a randomized controlled trial.
- Authors: Li X, Liu H, Feng H, Xian Z, Chen Y, Chen J, Tang C, Lai X, Lan X, Huang H, Yu D
- Issue date: 2017 Jun 28
- Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial.
- Authors: Grant SJ, Chang DH, Liu J, Wong V, Kiat H, Bensoussan A
- Issue date: 2013 May 14
- Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes.
- Authors: Suksomboon N, Poolsup N, Boonkaew S, Suthisisang CC
- Issue date: 2011 Oct 11
- Role of Purified Anthocyanins in Improving Cardiometabolic Risk Factors in Chinese Men and Women with Prediabetes or Early Untreated Diabetes-A Randomized Controlled Trial.
- Authors: Yang L, Ling W, Yang Y, Chen Y, Tian Z, Du Z, Chen J, Xie Y, Liu Z, Yang L
- Issue date: 2017 Oct 10
- Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial.
- Authors: Moreira-Lucas TS, Duncan AM, Rabasa-Lhoret R, Vieth R, Gibbs AL, Badawi A, Wolever TM
- Issue date: 2017 Jan